23.82
08-October-24 09:25:40
15 minutes delayed
Stocks
-0.38
-1.57%
Today's range
23.82 - 26.15
ISIN
N/A
Source
NASDAQ
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting
30 Sep 2024 07:00:00 By Nasdaq GlobeNewswire
MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
16 Sep 2024 15:05:00 By Nasdaq GlobeNewswire